Moderna (MRNA) Stock Keeps on Rising

Moderna (MRNA) Stock daily analysis results in Australia accepting Moderna's covid vaccine

The MRNA stock price fluctuated between $409.66 and $493.76 throughout the trading session with the volume trading being 42M shares, which represented a positive variation when compared to the three months average volume of 13M shares.

The share price of Moderna, Inc. (NasdaqGS:MRNA) ran up 17.1% to close Monday’s market session at $484.47, higher as compared to yesterday’s close which brings the market valuation of the company to $166.12B.

The 52-week high for the Moderna, Inc.’s shares is $443.99. This is the highest price the MRNA shares have gotten with a massive since the share price dropped to a 52-week low of $54.21.

The company currently has a 277.29 P/E ratio and a price target of $184.92.

Advertisements

What does the trading volume tell us about the MRNA stock?

During the last trading session, Moderna, Inc. (NasdaqGS:MRNA) has seen growth in its daily volume. The daily volume was of 13M, while in the last 10 days the average was 20.36M and last three months – 13.23M.

The increasing interest in the MRNA stock from the investors is helping to drive the stock price up.

Shrinking short interest

The Moderna, Inc.’s shares are seeing a decreasing short interest compared to the previous month. As of today, there are 11.83M shares being shorted which translates into 1.27 of a short ratio for MRNA, while in the previous month the shorted shares were 12.94M.

Advertisements

Moderna, Inc.’s (NasdaqGS:MRNA) financials

With a market cap of 166.12B, Moderna, Inc. holds a total cash of $7.74B that translates into $19.26 per share, while the total debt is of $279M.

The company has seen a decrease in the revenue with a year-over-year quarterly revenue growth percentage of 24,112.50%. The current revenue is of $2.73B that is $6.95 per share.

This is a not so good sign for the future.

Moderna (MRNA) Conquers New Highs

Moderna (MRNA) Stock today analysis pre market and after market
Advertisements

During the last session 32M of Moderna, Inc.’s (NasdaqGS:MRNA) shares were traded. The stock closed at $419.05 per share indicating that it gained $32.54 or 8.42% during that day which brings the Moderna, Inc.’s valuation to $168.26B.

The 52-week high for the Moderna, Inc.’s shares is $433.00. That puts it -3.22% from that peak but still a massive gain since the share price dropped to a 52-week low of $54.21, while the S&P 500’s share price change was of 33%.

The company currently has a 280.86 P/E ratio and a price target of $184.92.

What does the trading volume tell us about the MRNA stock?

During the last trading session, Moderna, Inc. (NasdaqGS:MRNA) has seen growth in its daily volume. The daily volume was of 13M, while in the last 10 days the average was 15.59M and last three months – 13.03M.


The increasing interest in the MRNA stock from the investors is helping to drive the stock price up.

Advertisements

Shrinking short interest

The Moderna, Inc.’s shares are seeing a decreasing short interest compared to the previous month. As of today, there are 11.83M shares being shorted which translates into 1.27 of a short ratio for MRNA, while in the previous month the shorted shares were 12.94M.

Moderna, Inc. (NasdaqGS:MRNA)’s financials

With a market cap of 168.26B, Moderna, Inc. holds a total cash of $7.74B that translates into $19.26 per share, while the total debt is of $279M.

The company has seen a decrease in the revenue with a year-over-year quarterly revenue growth percentage of 24,112.50%. The current revenue is of $2.73B that is $6.95 per share.


This is a ridiculously good sign for the future.